William Lewis Sells 18,750 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 18,750 shares of Insmed stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total value of $1,519,312.50. Following the completion of the sale, the chief executive officer now directly owns 334,186 shares in the company, valued at $27,079,091.58. This represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

William Lewis also recently made the following trade(s):

• On Thursday, February 6th, William Lewis sold 79,350 shares of Insmed stock. The stock was sold at an average price of $80.90, for a total value of $6,419,415.00.
• On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.94, for a total value of $1,461,375.00.
• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The stock was sold at an average price of $70.18, for a total value of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The stock was sold at an average price of $63.36, for a total value of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The stock was sold at an average price of $66.02, for a total value of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.91, for a total value of $1,310,812.50.

Insmed Trading Down 3.0 %

Shares of NASDAQ INSM opened at $81.06 on Friday. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The stock has a fifty day simple moving average of $74.29 and a 200-day simple moving average of $73.59. The stock has a market capitalization of $14.50 billion, a PE ratio of -14.61 and a beta of 1.11.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The company had revenue of $104.44 million during the quarter, compared to analysts’ expectations of $102.31 million. On average, equities analysts forecast that Insmed Incorporated will post -5.42 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Mackenzie Financial Corp grew its stake in Insmed by 12.5% during the 4th quarter. Mackenzie Financial Corp now owns 10,883 shares of the biopharmaceutical company’s stock worth $751,000 after purchasing an additional 1,213 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Insmed during the 4th quarter worth $259,000. Fourth Dimension Wealth LLC acquired a new position in Insmed during the 4th quarter worth $278,000. Vise Technologies Inc. grew its stake in Insmed by 6.3% during the 4th quarter. Vise Technologies Inc. now owns 5,634 shares of the biopharmaceutical company’s stock worth $389,000 after purchasing an additional 336 shares in the last quarter. Finally, Castleark Management LLC grew its stake in Insmed by 21.9% during the 4th quarter. Castleark Management LLC now owns 52,780 shares of the biopharmaceutical company’s stock worth $3,644,000 after purchasing an additional 9,480 shares in the last quarter.

Wall Street Analyst Weigh In

INSM has been the topic of a number of analyst reports. Truist Financial lifted their price objective on Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research report on Friday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research report on Wednesday. Morgan Stanley lifted their target price on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Wells Fargo & Company lifted their target price on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. lifted their target price on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $91.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.